Harrow Stock Soars 11% After Its Earnings Report — But It Cuts Its Annual Forecast

Quarterly revenue grew 38.6%, while the eye-drug company lowered its annual adjusted earnings target to more than $40 million.

Share
Harrow Stock Soars 11% After Its Earnings Report — But It Cuts Its Annual Forecast

Harrow, which sells eye medicines to eyecare professionals, soared 11.07% to $30.51 in Tuesday trading, as of 9:49 AM ET, adding $114 million in market value after Monday's earnings report. Its quarterly revenue grew 38.6% year over year to $99.3 million, according to the company's SEC filing, but it cut its annual adjusted earnings forecast.

Higher Sales, Lower Earnings Target

Harrow lowered its $80 million to $100 million annual adjusted earnings target to more than $40 million. The forecast reduction sat alongside the quarter's higher sales.

Mark L. Baum, Harrow's chief executive officer, said, "We expect the fourth quarter to be Harrow's strongest on record."

On Tuesday's earnings call, management said it plans to incorporate secondary findings from the QUELL eye-drug study into its messaging. The study missed its main goal, and management does not plan to repeat it for now.

A Rally After A 44% Slide

Harrow was on pace for its third straight daily gain in Tuesday trading, as of 9:49 AM ET, when its total market value was $1.14 billion.

Through Monday's close, the stock had lost 44% this year, compared with a 10% gain for the S&P 500. Before Tuesday's move, it was also 50% below its highest closing price of the past year.

Branded Drugs And Customized Eye Medicines

Harrow's business focuses mainly on the United States. Its branded medicines include IHEEZO, used to anesthetize the eye's surface; VEVYE, for dry eye disease; and TRIESENCE, a steroid injection for certain eye diseases. Outside manufacturers produce those drugs.

Its ImprimisRx compounding business prepares customized eye medications for ophthalmologists, optometrists and patients. Harrow's annual report for 2025 described two compounding facilities in Ledgewood, New Jersey, more than 30 formulations and a customer base exceeding 10,000 U.S. eyecare prescribers and institutions.

Harrow is also developing drug candidates for sedation and other eye-care uses.

Sources

More on Harrow

All Harrow (HROW) coverage →